Do ACE inhibitors influence the dose of human recombinant erythropoietin in dialysis patients?
Hess
E
E
Sperschneider
H
H
Stein
G
G
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000008:administration & dosage; D002216:Captopril / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004656:Enalapril / Q000008:administration & dosage; D004921:Erythropoietin / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D017328:Fosinopril / Q000008:administration & dosage; D006400:Hematocrit; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D006435:Renal Dialysis; D012189:Retrospective Studies
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D011994:Recombinant Proteins; D004921:Erythropoietin; D004656:Enalapril; D002216:Captopril; D017328:Fosinopril